An implantable cardioverter-defibrillator (ICD) was developed to provide
protection against sudden cardiac death. Despite being effective in terminating
ventricular arrhythmias, traditional transvenous ICDs appeared over time to have
certain limitations related to the need for vascular access and the presence of
foreign material inside the circulatory system (namely lead failure and
infections). A subcutaneous implantable cardioverter-defibrillator (S-ICD) was
developed to overcome those limitations and to provide prevention against sudden
cardiac death from outside the cardiovascular system. Utilization of that modern
method of treatment is constantly increasing worldwide, and new centers
incorporate implantation of that system in their portfolio. This review aims to
present the most relevant issues related to S-ICD implantation procedure, based
on experience of the authors and an extensive literature search.